Improved postoperative recovery profile in pediatric oral rehabilitation with low-dose dexmedetomidine as an opioid substitute for general anesthesia: a randomized double-blind clinical trial

Naik B Naveen¹, Manoj Kumar Jaiswal², Venkata Ganesh¹, Ajay Singh¹, Shyam Charan Meena¹, Vamsidhar Amburu³, Shiv Lal Soni¹

¹Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India
²Department of Pedodontics and Preventive Dentistry, Post Graduate Institute of Medical Education and Research, Chandigarh, India
³Department of Critical Care and Emergency Medicine, Sir Ganga Ram Hospital, New Delhi, India

**Background:** Low-dose dexmedetomidine may be a suitable alternative to opioids for pediatric ambulatory procedures under general anesthesia (GA). However, the recovery profile remains unclear. Herein, we aimed to evaluate the effects of low-dose dexmedetomidine on the recovery profile of children.

**Methods:** Seventy-two children undergoing ambulatory oral rehabilitation under GA were randomly and equally distributed into two groups (D and F). Group D received an infusion of dexmedetomidine 0.25 μg/kg for 4 min for induction, followed by maintenance of 0.4 μg/kg/h. Group F received an infusion of fentanyl 1 μg/kg over 4 min for induction, followed by maintenance at 1 μg/kg/h. The primary outcome was the extubation time. The secondary outcomes were awakening time, end-tidal sevoflurane (ET-Sevo) requirement, change in hemodynamic parameters, Richmond Agitation–Sedation Scale (RASS), Children's Hospital of Eastern Ontario pain scale (CHEOPS) score, length of PACU stay, and incidence of adverse events.

**Results:** Statistically significant differences were observed in the recovery profile between the groups: the median time for extubation was 3.65 (3.44–6.2) vs. 6.25 (4.21–7) minutes in groups D vs. F (P=0.001), respectively, while the corresponding awakening times were 19 (18.75–21) and 22.5 (22–24) minutes, respectively (P < 0.001). The mean ET-Sevo was low in group D (1.1 vs. 1.2; P < 0.001). The heart rate was significantly low across all time points in group D, without resulting in bradycardia. The median RASS and CHEOPS scores were also significantly lower in group D. No significant differences were observed in the mean arterial pressure, incidence of adverse events, or length of PACU stay.

**Conclusion:** Low-dose dexmedetomidine was more effective than fentanyl as an opioid substitute at providing a better recovery profile in pediatric ambulatory oral rehabilitation under GA. Dexmedetomidine also significantly reduced sevoflurane consumption without causing adverse events or prolonging hospital stay.

**Keywords:** Children; Dental Care; Dexmedetomidine; Recovery.

INTRODUCTION

Over the past few decades, several studies have shown a significant increase in early childhood dental caries (ECC) worldwide [1,2], with children under the age of six being especially vulnerable [2]. Recently, health professionals have been challenged by immense demands
and an increase in the number of such patients [1]. The purpose of providing general anesthesia (GA) in uncooperative pediatric patients with ECC is to restore optimum dental health in one visit and prevent apprehension related to multiple dental chair visits, which necessitates substantial dental work [3]. Ensuring a suitable anesthetic approach in this scenario is essential for ensuring risk-free, prompt, effective, and cost-efficient anesthesia.

Opioids have been a central component of routine pediatric anesthesia for decades. However, their side effects include respiratory distress, itching, retention of urine, nausea, vomiting, constipation, mood changes, and unintentional opioid dependence among children [4-7]. Fentanyl can augment hyperalgesia [8]. However, there is inadequate data to establish an outcome [9]. Recently, there has been a trend towards use opioid-free anesthesia in pediatric ambulatory procedures [10-12]. An ideal opioid-free anesthetic agent should be rapid in onset and offset, with smooth emergence, minimal cardiovascular effects, and a predictable response. As a highly selective α-2 adrenergic agonist, dexmedetomidine possesses several of these desirable properties, which are beneficial in the ambulatory setting [13-15]. Dexmedetomidine exhibits anxiolytic, analgesic, sympatholytic, and opioid-sparing effects at low doses (< 0.5 μg/kg) [15-21]. Many pediatric studies have also reported other benefits of low-dose dexmedetomidine [16-21], such as decreased incidence of emergence agitation [19,22,23], emergence delirium [19,24], postoperative pain [23,19], and reduced sevoflurane consumption [19] with a better hemodynamic profile [18-21]. However, evidence related to the recovery characteristics of low-dose dexmedetomidine is scarce. To our knowledge, no study has evaluated the opioid-equivalent efficacy of low-dose dexmedetomidine in pediatric patients for GA, although this has been reported in adults [15,25].

We designed this randomized controlled trial to compare the recovery parameters of low-dose dexmedetomidine and fentanyl in children undergoing ambulatory oral rehabilitation dental procedures under GA. We speculated that the application of low-dose dexmedetomidine as an opioid substitute would accelerate recovery. We also analyzed the effects of low-dose dexmedetomidine on hemodynamic indices, sevoflurane requirement, length of PACU stay, incidence of adverse events, postoperative sedation, and pain profile.

**METHODS**

1. **Study design**

This randomized, controlled, double-blind clinical trial was conducted at the Oral Health Sciences Center of the Post Graduate Institute of Medical Education and Research, Chandigarh, a tertiary care hospital in India. We aimed to compare the recovery characteristics of fentanyl and low-dose dexmedetomidine in pediatric patients undergoing ambulatory oral rehabilitation under GA.

2. **Ethics**

After obtaining approval from the institutional ethics committee, the trial was registered in the clinical trial registry of India (CTRI/2019/01/017252). Before enrolment and randomization to the study arms, written informed consent was obtained from the parents/legal guardians of the patients.

3. **Participants**

Children aged 1 to 4 years with American Society of Anesthesiologists (ASA) physical status I and II were included. Children with a history of allergy to any anesthetic agent, renal or liver dysfunction, or those who disallowed premedication were excluded from the trial.

4. **Randomization**

Pediatric patients were randomly and equally allocated into two groups (D and F) using a computer-based simple randomization method. Group D received a bolus dose of dexmedetomidine 0.25 μg/kg over 4 mins for induction, followed by a maintenance infusion of 0.4 μ
g/kg/h until 10 mins before the end of the procedure. Group F received a bolus dose of fentanyl 1 μg/kg over 4 min for induction, followed by a maintenance infusion of 1 μg/kg/h until 10 min before the end of the procedure. The drugs were prepared by a separate anesthesiologist who was not involved in the study who received information regarding the drugs to use in a sealed envelope. The drugs were diluted in 50 ml of normal saline and administered through a syringe infusion pump by a blinded anesthesiologist. Coded labels (drugs 1 or 2) were affixed over the 50 cc syringe so that the attending anesthesiologist would be unaware of the grouping of the children. Thus, the syringes and volumes of the prepared solutions were the same; only the rate of drug infusion differed according to the weight of each child. The anesthesiologist, pedodontist, and observer were blinded to the study protocol. The master code was in the possession of an individual not involved in the trial.

5. Anesthesia

In the preoperative recovery room, children were premedicated using midazolam syrup 0.5 mg/kg orally, 20 minutes before induction of anesthesia. After shifting inside the procedure room, ASA standard monitors and bispectral index (BIS) electrodes were attached to ensure not to agitate the child. Venous cannulation was secured after inhalation induction using 5–8% sevoflurane with 100% oxygen. Anesthesia induction was initiated with infusion bolus doses of low-dose dexmedetomidine (group D) or fentanyl (group F) at the doses mentioned above in the randomization. After checking for adequate bag and mask ventilation, the muscle relaxant atracurium 0.5 mg/kg was administered intravenously, and anesthesia was maintained with sevoflurane, targeting a BIS of 50. After 4 min, the airway was secured with an endotracheal tube, and mechanical ventilation was initiated with a tidal volume of 6–8 ml/kg to sustain normocapnia (35–45 mmHg), guided by end-tidal CO2 monitoring. Anesthesia was maintained using a continuous intravenous infusion of low-dose dexmedetomidine or fentanyl, oxygen, and N₂O mixture (50:50), and sevoflurane. The ET-Sevo was adjusted to attain a BIS of 50 throughout the procedure. As a routine institutional practice, body temperature was monitored throughout the procedure, and forced air-warm blankets and warm intravenous fluids were administered to maintain normothermia. At the end of the procedure, 15 mg/kg of intravenous paracetamol was administered for analgesia. Intravenous infusion of fentanyl or dexmedetomidine was stopped 10 minutes before the end of the procedure. At the end of the procedure, sevoflurane and nitrous oxide were discontinued, and the child was extubated after the return of spontaneous respiration and adequate muscle tone. The children were then moved to the PACU, and a parent was allowed to accompany the child. Until their discharge from the PACU, patients were monitored continuously by a trained nurse or anesthesiologist who was blinded to the study trial.

6. Outcome and measurements

The primary outcome was the time for extubation (time from the end of surgery until removal of the endotracheal tube). The secondary outcomes were awakening time (time from the end of drug infusion to eye opening in response to a voice), ET-Sevo requirement, percentage change in hemodynamic parameters, sedation scoring, pain scoring, length of PACU stay, rescue analgesia requirement, incidence of vomiting, incidence of emergence agitation, and any other adverse events.

Perioperative hemodynamic parameters (heart rate [HR], systolic, diastolic, and mean arterial pressure [MAP]) were obtained at the following time points: at baseline, at the initiation of the loading dose, after the loading dose, post-intubation, every 10 min during the procedure, after extubation, on arrival at the PACU, and every 15 min until discharge from the PACU. The Richmond agitation sedation score (RASS) was used for sedation assessment from the time of arrival at the PACU until discharge, with a score range of −5 (no response to voice or physical stimulation) to +4 (overtly combative or violent). Post-procedure pain was evaluated using the Children's Hospital of Eastern Ontario Pain Scale (CHEOPS; 4–13 score range). A CHEOPS score of > 6
was regarded as an endpoint for rescue analgesia with intravenous fentanyl 0.5 μg/kg. Children with modified Aldrete scores ≥ 9 were deemed fit for discharge from the PACU.

7. Statistics

The calculated sample size was 36 per group, with a 95% confidence interval (two-sided), considering an 80% power of the study and significance level of 5%, and to demonstrate a difference of 2.7 minutes with a pooled SD of 3.8 [16] in the primary objective between groups and considering a dropout rate of 10%. Unpaired t-tests or Mann-Whitney U tests were used to compare continuous data based on the normality of distribution. Repeated measures were analyzed using repeated-measures ANOVA or GEE (Generalized Estimating Equations, with exchangeable correlation matrix and identity link function). Pairwise comparisons were adjusted using the Bonferroni correction. Categorical data were compared using the chi-squared test. Statistical significance was set at P < 0.05. All analyses were performed using the Stata 15 software (StataCorp. 2017. Stata statistical software: Release 15. College Station, TX, StataCorp LLC).

RESULTS

In total, 83 children were initially enrolled in the study (Fig. 1), of whom 72 were subsequently randomized after fulfillment of the eligibility criteria. The baseline demographic parameters were comparable between the two groups (Table 1). There were no significant differences in age, sex, weight, procedure time, baseline heart rate, or mean MAP.

The time to extubation (represented as the median [Q1,
Table 1. Demographic and baseline variables

|                        | Dexmedetomidine (n = 36) | Fentanyl (n = 36) | P-value |
|------------------------|--------------------------|------------------|---------|
| Age (years), mean (SD) | 2.6 (0.9)                | 2.5 (0.6)        | 0.486a  |
| Weight (kg), mean (SD) | 12.3 (2.2)               | 12.6 (2.9)       | 0.525a  |
| Gender (male/female), number (%) | 25 (69.4) / 11 (30.6) | 19 (52.8) / 17 (47.2) | 0.147b |
| Duration of surgery (in min), mean (SD) | 96.3 (7.9) | 93.9 (11.3) | 0.294a  |
| Mean arterial pressure (mmHg), mean (SD) | 63.0 (3.6) | 59.6 (2.4) | 1.000a  |
| Heart rate (bpm), mean (SD) | 133.8 (6.2) | 131.3 (7.4) | 0.133a  |

*aUnpaired T test, bChi-square test; *P < 0.05 has been considered significant. n, number; SD, standard deviation.

Q3]) was significantly shorter in group D (3.65 [3.44–6.2] vs. 6.25 [4.21–7]; *P = 0.001) than in group F. Awakening time was also significantly reduced in the dexmedetomidine group (19 [18.75–21] vs. 22.5 [22–24]; *P < 0.001).
Table 2. Outcome parameters

|                           | Dexmedetomidine (n = 36) | Fentanyl (n = 36) | P-value |
|---------------------------|--------------------------|------------------|---------|
| Time to extubate, median Q1,Q3 | 3.65 [3.44–6.2]          | 6.25 [4.21–7]   | 0.001*  |
| Awakening time(min), median Q1,Q3 | 19.0 [18.75–21]          | 22.5 [22–24]    | < 0.001*|
| Mean end-tidal sevoflurane (%), mean (SD) | 1.1 (0.0)               | 1.2 (0.0)       | < 0.001*|
| PACU Stay (min), mean (SD) | 53.3 (4.0)               | 55.8 (8.0)      | 0.106a  |
| Need for rescue analgesia, number (%) | 7 (19.4)                | 10 (27.8)       | 0.405b  |
| CHEOPS immediate post-procedure, median Q1,Q3 | 5.0 [5.0, 5.0]       | 5.0 [5.0,5.0]   | 0.392c  |
| CHEOPS 10 minutes post-procedure, median Q1,Q3 | 4.5 [4.0, 5.0]       | 5.0 [4.0,5.0]   | 0.463c  |
| RASS immediate post-procedure, median Q1,Q3 | 0.0 [0.0, 0.0]        | 1.0 [1.0,1.0]   | < 0.001c|
| RASS at 10 minutes post-procedure, median Q1,Q3 | -1.0 [-1.0, -1.0]   | 0.0 [0.0,1.0]   | < 0.001c|

*aUnpaired T test, *cChi-square test, *mMann-Whitney U test. P < 0.05 has been considered significant. CHEOPS, Children’s Hospital of Eastern Ontario pain scale; n, number; PACU, post anesthesia care unit; Q, quartile; RASS, Richmond agitation-sedation scale; SD, standard deviation.

Intraoperatively, the ET-Sevo concentration required to maintain a BIS of 50 was lower at almost all time points in the dexmedetomidine group than in the fentanyl group, as shown in Figure 2C. This difference was statistically significant (1.2% vs. 1.1%; P < 0.001; Table 2).

Intraoperative heart rate was lower in the dexmedetomidine group than in the fentanyl group at most points in time (Fig. 2A and 3A), showing a significant group time interaction both intraoperatively (P < 0.025, Table 3) and postoperatively (P = 0.056).
Table 3. Analysis of repeated measures

| Variable                  | Effect of group (P-value) | Effect of time (P-value) | Effect of group over time (P-value) | Test   |
|---------------------------|---------------------------|--------------------------|-----------------------------------|--------|
| Intraoperative Heart rate | 0.135                     | < 0.001                  | 0.023                             | ANOVA  |
| Intraoperative MAP        | 0.378                     | < 0.001                  | 0.107                             | ANOVA  |
| Intraoperative Sevoflurane| < 0.001                   | < 0.001                  | < 0.001                           | ANOVA  |
| Post-procedure Heart rate| < 0.001                   | 0.017                    | 0.056                             | ANOVA  |
| Post-procedure MAP        | 0.682                     | 0.245                    | 0.267                             | ANOVA  |
| CHEOPS score              | 0.124                     | 0.038                    | 0.027                             | GEE    |
| Post-procedure RASS score | 0.087                     | 0.470                    | 0.001                             | GEE    |

P < 0.05 is considered as statistically significant. ANOVA, analysis of variance; CHEOPS, Children’s Hospital of Eastern Ontario pain scale; GEE, generalized estimating equations; MAP, mean arterial pressure; RASS, Richmond agitation sedation score.

However, there were no significant differences in the perioperative MAP among the groups (Table 3; Fig. 2B and 3B). Moreover, none of the patients developed bradycardia (defined as an HR decrease of ≥ 30% from the baseline value) or hypotension throughout the study period.

After the dental procedure, the median RASS and CHEOPS scores with quartiles (Q1 and Q3) were analyzed (Fig. 3C and 3D). The RASS was significantly lower in the dexmedetomidine group over time (P = 0.001; Table 2). The CHEOPS score was also lower in the dexmedetomidine group over time (P = 0.027; Fig. 3C). However, this difference was more due to changes in CHEOPS over time (P = 0.038; Table 3) than due to the treatment effect (P = 0.124; Table 3). Rescue analgesia was required in 10 (27.8%) children in the fentanyl group and 7 (19.4%) in the dexmedetomidine group (P = 0.405; Table 2).

The mean (SD) duration of PACU stay was comparable between the fentanyl and dexmedetomidine groups (55.8 [8] and 53.3 [4] min, respectively; P = 0.106). Out of 72 patients, four experienced vomiting episodes in the fentanyl group compared with none in the dexmedetomidine group; however, this difference was not statistically significant.

DISCUSSION

The use of GA for pediatric dental treatment of ECC has shown an increasing trend [25], mainly because of the state of cognitive function in children at that stage and the complexity of oral rehabilitation, especially in those with multiple dental caries [2,26].

Anesthesiologists generally use dexmedetomidine in the pediatric population for premedication and procedural sedation as an opioid-sparing agent [27], and to avert and treat postoperative emergence agitation [14]. Although there is a substantial body of evidence on dexmedetomidine use in pediatric patients, studies on its opioid-equivalent efficacy and recovery characteristics are scarce. Low-dose dexmedetomidine has been studied as an opioid substitute in adults [15,25]; however, to our knowledge, this is the first RCT evaluating the opioid substitution property and recovery characteristics of low-dose dexmedetomidine against fentanyl in a pediatric population.

The recovery characteristics of dexmedetomidine are related to its infusion dose and rate; with increasing dosage, the recovery time is significantly prolonged [17]. Our selection of 0.25 μg/kg loading dose of dexmedetomidine was based on a recent RCT by Sun et al. involving children (1–5 years of age) undergoing laparoscopic hernia repair [19]. They demonstrated a shorter recovery time with smooth emergence at low doses of dexmedetomidine. Conversely, as there is no recommended dose of dexmedetomidine in the 1–5-year-old population, different dosing and rate of infusions were used in every published study [17-20]. In a study by Chen et al. [17], dexmedetomidine at different
doses (0.25, 0.5, 0.75, and 1.0 μg/kg) was administered intraoperatively at a rate of less than 5 s. Conversely, Zhou et al. [18] administered low-dose dexmedetomidine of 0.5 μg/kg within 3 minutes preoperatively, while Xie et al. [20] administered dexmedetomidine at a loading dose of 0.5 μg/kg over 10 mins for anesthesia induction, followed by maintenance of 0.5 μg/kg/h.

Our findings suggest that low-dose dexmedetomidine as an opioid substitute drug provides a good recovery profile with stable hemodynamics and without prolonging hospital stay in children undergoing ambulatory oral rehabilitation procedures under GA. The shorter recovery time associated with low-dose dexmedetomidine in our study was consistent with the findings of a recent meta-analysis [21], which reported a significantly shorter recovery time (5.9 minutes with low-dose dexmedetomidine). Nevertheless, the definition of recovery time differed in the included RCTs. Certain studies [19,20] defined it as the time to spontaneous eye-opening post-extubation, whereas another RCT [17] defined it as the duration of PACU stay.

Inhalational volatile anesthetics, particularly sevoflurane, have been associated with increased agitation [23] and delirium [24] during emergence from anesthesia in the pediatric population. Dexmedetomidine at low doses decreases both emergence agitation and delirium by reducing the requirement for sevoflurane [19], although evidence to support this in children is scarce [23,24]. In our study, 0.25 μg/kg of dexmedetomidine followed by a maintenance infusion of 0.4 μg/kg decreased sevoflurane requirement by 16.7%. A previous study demonstrated that 0.5 μg/kg of dexmedetomidine decreased sevoflurane requirement by 33% in children undergoing minor surface surgery under GA [28]. However, we believe that their induction doses of dexmedetomidine (1–2 μg/kg) were high under GA. Several studies have reported severe bradycardia [29,30] and cardiac arrest [31,32] with high-bolus dosing regimens of dexmedetomidine in pediatric patients owing to its unpredictable hemodynamic response. Mason et al. reported that the dosing and rate of dexmedetomidine infusion significantly impacted the hemodynamic profile of patients [29]. Conversely, in a recent meta-analysis, Josephine et al. [21] reported a better hemodynamic profile and shorter recovery time with ≤ 0.5μg/kg of dexmedetomidine than those associated with higher doses (> 0.5 μg/kg).

No cases of hypotension or bradycardia were reported in either study group, since both fentanyl and low-dose dexmedetomidine were infused slowly over 4 minutes, instead of in a quick bolus. The HR was significantly lower at most time points in the dexmedetomidine group. However, MAP was normal in all patients. The maximum decrease in mean HR from baseline in the dexmedetomidine group was 26% and the maximum decrease in MAP was 17%, which was clinically insignificant. Chen et al. [17] reported a similar decrease in HR of less than 30% from the baseline following the administration of dexmedetomidine at doses of 0.25 and 0.5 μg/kg in children. However, this difference was clinically insignificant, and no patient required any additional treatment.

In the dexmedetomidine group, all children were calm post-extubation and had significantly lower RASS and CHEOPS scores with no incidence of emergence agitation. Our findings support the high-quality evidence from a recent meta-analysis by Zhang et al. [33], which demonstrated the benefits of maintenance infusion of dexmedetomidine on emergence agitation in children. Our findings also demonstrate that dexmedetomidine minimizes PONV and the need for rescue analgesia without delaying discharge from the PACU. These findings are consistent with those of earlier meta-analyses [33-35].

Our study had two main limitations. First, we did not include a placebo-controlled group; unfortunately, this was not feasible, as not administering any opioid or non-opioid analgesic can trigger acute emergence delirium, and ambulatory anesthesia may not be possible due to parents’ apprehension due to the children's unusual behavior post-procedure. Second, we compared fentanyl and dexmedetomidine based on their optimum and safe
Dosing for ambulatory procedures, without considering their equivalent doses. To further elucidate our findings, a future pharmacokinetic/pharmacodynamic clinical dose-response study may be necessary.

In conclusion, fentanyl and low-dose dexmedetomidine were comparable in terms of safety, analgesic requirement, and length of PACU stay. Our findings showed a rapid and smooth recovery with low-dose dexmedetomidine than fentanyl, which implies that dexmedetomidine at a dose < 0.4 μg/kg can be used safely as an opioid substitute. Multi-centric studies incorporating a wide range of cases and procedure settings in the pediatric population are warranted to establish the promising role of low-dose dexmedetomidine as an opioid substitute for GA.

CONFLICTS OF INTEREST: The authors have no potential conflicts of interest (financial or nonfinancial) to declare.

REFERENCES

1. Wen PYF, Chen MX, Zhong Yj, Dong QQ, Wong HM. Global burden and inequality of dental caries, 1990 to 2019. J Dent Res 2022; 101: 392-9.
2. Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJ, Marcenes W. Global burden of untreated caries: a systematic review and metaregression. J Dent Res 2015; 94: 650-8.
3. Oubenyahya H, Bouhabba N. General anesthesia in the management of early childhood caries: an overview. J Dent Anesth Pain Med 2019; 19: 313-22.
4. Koepke EJ, Manning EL, Miller TE, Ganesh A, Williams DGA, Manning MW. The rising tide of opioid use and abuse: the role of the anesthesiologist. Perioper Med (Lond) 2018; 7: 16.
5. Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy 2013; 33: 383-91.
6. Bennett KG, Harbaugh CM, Hu HM, Verder CJ, Buchman SR, Brummett CM, et al. Persistent opioid use among children, adolescents, and young adults after common cleft operation. J Craniofac Surg 2018; 29: 1697-701.
7. Swartz MK. Opioids: a pediatric epidemic. J Pediatr Health Care 2018; 32: 115-6.
8. Mauermann E, Filitz J, Dolder P, Rentsch KM, Bandschapp O, Ruppen W. Does fentanyl lead to opioid-induced hyperalgesia in healthy volunteers? A double-blind, randomized, crossover trial. Anesthesiology 2016; 124: 453-63.
9. Fletcher D, Martinez V. Opioid-induced hyperalgesia in
patients after surgery: a systematic review and a meta-analysis. Br J Anaesth 2014; 112: 991-1004.

10. Chiem JL, Donohue LD, Martin LD, Low DK. An opioid-free anesthesia protocol for pediatric strabismus surgery: a quality improvement project. Pediatr Qual Saf 2021; 6: e462.

11. Franz AM, Martin LD, Liston DE, Latham GJ, Richards MJ, Low DK. In pursuit of an opioid-free pediatric ambulatory surgery center: a quality improvement initiative. Anesth Analg 2021; 132: 788-97.

12. Rizeq YK, Many BT, Vacek JC, Silver I, Goldstein SD, Abdullah F et al. Trends in perioperative opioid and non-opioid utilization during ambulatory surgery in children. Surgery 2019; 166: 172-6.

13. Mohamed M, Mason KP. Dexmedetomidine and ambulatory surgery. ASA Newsletter 2015; 79: 24-6.

14. Mahmoud M, Mason KP. Dexmedetomidine: review, update, and future considerations of paediatric perioperative and periprocedural applications and limitations. Br J Anaesth 2015; 115: 171-82.

15. Ganesh V, Luthra A, Amburu V, Naik BN, Singh A, Puri GD. Low-dose dexmedetomidine reduces median effective concentration (ec 50) of propofol more than fentanyl in unparalysed anaesthetised patients for i-gel insertion: a randomised controlled trial. Anaesth Crit Care Pain Med 2021; 40: 100815.

16. Erdil F, Demirbilek S, Begec Z, Ozturk E, Ulger MH, Ersoy MO. The effects of dexmedetomidine and fentanyl on emergence characteristics after adenoidectomy in children. Anaeath Intensive Care 2009; 37: 571-7.

17. Chen F, Wang C, Lu Y, Huang M, Fu Z. Efficacy of different doses of dexmedetomidine as a rapid bolus for children: a double-blind, prospective, randomized study. BMC Anesthesiol 2018; 18: 103.

18. Zhou M, Wang Q, Zhang Q, Liu Y, Zhan L, Shu A. Application of pre-injection of dexmedetomidine of different doses in pediatric intravenous general anesthesia without tracheal intubation. Exp Ther Med 2018; 15: 2973-7.

19. Sun Y, Li Y, Sun Y, Wang X, Ye H, Yuan X. Dexmedetomidine effect on emergence agitation and delirium in children undergoing laparoscopic hernia repair: a preliminary study. J Int Med Res 2017; 45: 973-83.

20. Xie Y, Du Y, Shi H, Sun J, Duan H, Yu J. Different doses of dexmedetomidine in children with non-tracheal intubation intravenous general anesthesia. Int J Clin Exp Med 2018; 11: 6215-21.

21. Josephine C, Sharifuddin II, Chaw SH, Ng KWS, Ng KT. Hemodynamic response of high- and low-dose dexmedetomidine of pediatric in general anesthesia: a systematic review and meta-analysis of randomized controlled trials. Asian J Anesthesiol 2021; 59: 7-21.

22. Kim J, Kim SY, Lee JH, Kang YR, Koo BN. Low-dose dexmedetomidine reduces emergence agitation after desflurane anaesthesia in children undergoing strabismus surgery. Yonsei Med J 2014; 55: 508-16.

23. Sato M, Shirakami G, Tazuke-Nishimura M, Matsuura S, Tanimoto K, Fukuda K. Effect of single-dose dexmedetomidine on emergence agitation and recovery profiles after sevoflurane anesthesia in pediatric ambulatory surgery. J Anesth 2010; 24: 675-82.

24. Shi M, Miao S, Gu T, Wang D, Zhang H, Liu J. Dexmedetomidine for the prevention of emergence delirium and postoperative behavioral changes in pediatric patients with sevoflurane anesthesia: a double-blind, randomized trial. Drug Des Devel Ther 2019; 13: 897-905.

25. Jебaraj B, Ramachandran R, Rewari V, Trikha A, Chandradekha, Kumar R, et al. Feasibility of dexmedetomidine as sole analgesic agent during robotic urological surgery: a pilot study. J Anaesthesiol Clin Pharmacol 2017; 33: 187-92.

26. Chen YP, Hsieh CY, Hsu WT, Wu FY, Shih WY. A 10-year trend of dental treatments under general anesthesia of children in Taipei Veterans General Hospital. J Chin Med Assoc 2017; 80: 262-8.

27. van Hoom CE, Flint RB, Skowno J, Davies P, Engelhardt T, Lalwani K et al. Off-label use of dexmedetomidine in paediatric anaesthesiology: an international survey of 791 (paediatric) anaesthesiologists. Eur J Clin Pharmacol 2021; 77: 625-35.

28. He I, Wang X, Zheng S. Effects of dexmedetomidine on sevoflurane requirement for 50% excellent tracheal
intubation in children: a randomized, double-blind comparison. Paediatr Anaesth 2014; 24: 987-93.
29. Mason KP, Lerman J. Review article: dexmedetomidine in children: current knowledge and future applications. Anesth Analg 2011; 113: 1129-42.
30. Gong M, Man Y, Fu Q. Incidence of bradycardia in pediatric patients receiving dexmedetomidine anesthesia: a meta-analysis. Int J Clin Pharm 2017; 39: 139-47.
31. Videira RL, Ferreira RM. Dexmedetomidine and asystole. Anesthesiology 2004; 101: 1479-80.
32. Ingersoll-Weng E, Manecke GR Jr, Thistlethwaite PA. Dexmedetomidine and cardiac arrest. Anesthesiology 2004; 100: 738-9.
33. Zhang X, Bai Y, Shi M, Ming S, Jin X, Xie Y. Effect of different administration and dosage of dexmedetomidine in the reduction of emergence agitation in children: a meta-analysis of randomized controlled trials with sequential trial analysis. Transl Pediatr 2021; 10: 929-57.
34. Tang W, He D, Liu Y. Effect of Dexmedetomidine in children undergoing general anaesthesia with sevoflurane: a meta-analysis and systematic review. J Int Med Res 2020; 48: 300060520927530.
35. Yang X, Hu Z, Peng F, Chen G, Zhou Y, Yang Q, et al. Effects of dexmedetomidine on emergence agitation and recovery quality among children undergoing surgery under general anesthesia: a meta-analysis of randomized controlled trials. Front Pediatr 2020; 8: 580226